Cytek Biosciences to Participate in the UBS MedTech, Tools and Genomics Summit
- Cytek Biosciences, Inc. will be participating in the 2023 UBS MedTech, Tools and Genomics Summit in Dana Point, CA. They will be joining the Emerging Life Science Technologies Across Genomics and Proteomics panel on August 16th. Cytek management will also have one-on-one meetings with investors on August 16th and 17th.
- None.
FREMONT, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 2023 UBS MedTech, Tools and Genomics Summit in Dana Point, CA.
Cytek management is scheduled to participate in the Emerging Life Science Technologies Across Genomics and Proteomics panel on Wednesday, August 16th at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern Time. Cytek management will be participating in one-on-one meetings with investors on Wednesday, August 16th and Thursday, August 17th.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system and certain reagents for use therewith, which are available for clinical use in countries where the regulatory approval has been obtained from the local regulatory authorities, including China and the European Union, Cytek’s products are for research use only and not for use in diagnostic procedures.
Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and corporate "X” account (formerly Twitter) as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com
FAQ
When is Cytek Biosciences participating in the UBS MedTech, Tools and Genomics Summit?
What panel will Cytek Biosciences join at the summit?
Will Cytek Biosciences have meetings with investors during the summit?
